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Abstract
In premature infants, glucocorticoids ameliorate chronic lung disease, but have adverse effects on long-term neurological
function. Glucocorticoid excess promotes free radical overproduction. We hypothesised that the adverse effects of postnatal
glucocorticoid therapy on the developing brain are secondary to oxidative stress and that antioxidant treatment would
diminish unwanted effects. Male rat pups received a clinically-relevant tapering course of dexamethasone (DEX; 0.5, 0.3, and
0.1 mg.kg21.day21), with or without antioxidant vitamins C and E (DEXCE; 200 mg.kg21.day21 and 100 mg.kg21.day21,
respectively), on postnatal days 1–6 (P1–6). Controls received saline or saline with vitamins. At weaning, relative to controls,
DEX decreased total brain volume (704.4634.7 mm3 vs. 564.0620.0 mm3), the soma volume of neurons in the CA1
(1172.6630.4 mm3 vs. 1002.4611.8 mm3) and in the dentate gyrus (525.9627.2 mm3 vs. 421.5624.6 mm3) of the
hippocampus, and induced oxidative stress in the cortex (protein expression: heat shock protein 70 [Hsp70]: +68%; 4-
hydroxynonenal [4-HNE]: +118% and nitrotyrosine [NT]: +20%). Dexamethasone in combination with vitamins resulted in
improvements in total brain volume (637.5643.1 mm3), and soma volume of neurons in the CA1 (1157.5642.4 mm3) and
the dentate gyrus (536.1627.2 mm3). Hsp70 protein expression was unaltered in the cortex (+9%), however, 4-HNE (+95%)
and NT (+24%) protein expression remained upregulated. Treatment of neonates with vitamins alone induced oxidative
stress in the cortex (Hsp70: +67%; 4-HNE: +73%; NT: +22%) and in the hippocampus (NT: +35%). Combined glucocorticoid
and antioxidant therapy in premature infants may be safer for the developing brain than glucocorticoids alone in the
treatment of chronic lung disease. However, antioxidant therapy in healthy offspring is not recommended.
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Introduction
Glucocorticoids are widely used to treat or prevent chronic lung
disease (CLD) in preterm infants [1–5]. A major contributor to
the development of CLD is excessive inflammation and thus
glucocorticoids are used to prevent or reduce the severity of this
complication due to their anti-inflammatory properties [4,6,7].
Despite established benefits, randomized clinical trials of postnatal
steroid therapy have raised concerns regarding an increase in the
rates of cerebral palsy and adverse neuromotor and cognitive
outcomes [8,9]. Furthermore, experimental studies in neonatal
animals have demonstrated adverse effects of potent glucocorti-
coids, such as dexamethasone on brain growth, cell division,
differentiation, myelination, apoptosis, and neurogenesis [10–15].
Clinically, therefore, the weaker glucocorticoid hydrocortisone is
the steroid of choice [16]. The use of dexamethasone being
particularly reserved for extremely premature (,32 weeks) and
low birth weight infants unlikely to survive without therapy [17].
However, whilst hydrocortisone appears to cause fewer unwanted
adverse effects than dexamethasone, it is also less potent in
promoting the beneficial effects of glucocorticoids [16,18,19].
For these reasons, there is increasing clinical and basic science
interest in persisting with the clinical use of potent steroids, such
as dexamethasone, as long as the adverse side effects can be
controlled. However, the mechanism underlying the unwanted
side effects remains unknown, preventing the identification of
plausible modified therapies to maintain the beneficial effects but
prevent adverse side-effects.
Accumulating evidence suggests that glucocorticoids can
promote oxidative stress in various tissues including the heart
and vasculature [20–24] and kidney [21]. In relation to the brain,
glucocorticoids increase the presence of reactive oxygen species
(ROS) in both hippocampal and cortical cultures [25], and lower
basal activity of cerebral antioxidant enzymes [26]. Furthermore,
in vitro studies have shown that exposure to glucocorticoids can
increase the susceptibility of cerebellar granule cells [27] and
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hippocampal neurons [28] to oxidative stress-induced cell death.
Reactive oxygen species are produced under physiological
conditions during metabolic reactions and functioning of the
central nervous system [29]. However, excess ROS generation can
cause cellular damage directly by attacking proteins, and
indirectly, by generating further reactive species and initiating
radical chain reactions [30]. Non-enzymatic and enzymatic
antioxidants provide defence mechanisms against excess ROS
production. The former include the water soluble vitamin C and
the fat soluble vitamin E. Vitamin C is the most effective aqueous-
phase antioxidant in human blood plasma because of its ability to
trap peroxyl radicals, thereby preventing lipid peroxidation [31].
Vitamin E is a peroxyl radical scavenger and one of the most
important inhibitors of the free-radical chain reaction of lipid
peroxidation, giving it a major role in protecting biological
membranes [32]. Antioxidant treatment has been shown to
prevent and partially restore glucocorticoid-induced vascular
dysfunction [23] and hypertension [24], further supporting the
premise that oxidative stress may be the underlying mechanism
mediating unwanted side-effects of glucocorticoids.
Whilst ROS have been implicated in the pathogenesis of various
neurodegenerative disorders including Parkinson’s and Alzhei-
mer’s disease [33–35], the role of ROS in the pathogenesis of
glucocortocoid-induced brain injury during early development,
remains unclear. In this study, we have combined these separate
lines of evidence to propose the inter-related hypotheses that the
adverse effects of postnatal glucocorticoid therapy on the
developing brain are secondary to oxidative stress and that
antioxidant treatment would diminish unwanted effects. The
hypothesis was tested using a well established model of postnatal
glucorticoid therapy in rats [36,37].
Methods
Ethical Approval
The study was approved by the Cambridge University Ethical
Review Committee. All procedures were carried out under the
UK Animals (Scientific Procedures) 1986 Act and conducted
under the authority of roject icenc .
Animals and Experimental Design
Twenty-five pregnant Wistar rats (Charles River, UK) with timed
gestations were individually housed under standard conditions
(2361uC, light:dark, 12:12 hour) with access to food (Special Diet
Services, UK) and water. All dams delivered on day 22 of gestation
(assigned postnatal day 0, P0). Litters were then divided into four
treatment groups: control (Ctrl, n = 6), dexamethasone (DEX,
n=6), dexamethasone with vitamins C and E (DEXCE, n= 7), and
control with vitamins C and E (CtrlCE, n= 6).
Within 3–5 hours of birth, pups were sexed and weighed, and
litters reduced to 8 pups per dam (four males and four females) in
order to standardize postnatal nutrition and maternal care. To
account for sex differences, only male pups within each litter
received treatment (Ctrl, n = 24; DEX, n= 24; DEXCE, n= 28;
and CtrlCE, n= 24). Male pups received two intraperitoneal (i.p.)
injections daily (10 mL.g21 for each) of some or all of the following
solutions from Sigma (Sigma-Aldrich, UK): Dexamethasone
(Dexamethasone-21-phosphate, disodium salt), vitamin C (L-
ascorbic acid), and vitamin E (dl-a-tocopherol acetate). Two
injections were used due to the different solubilities of vitamin E
(dissolved in groundnut oil) and vitamin C and dexamethasone
(both dissolved in 0.9% NaCl). Ctrl pups received injections of
saline and groundnut oil for the duration of the treatment period,
postnatal days 1–6 (P1–6). Dexamethasone pups received a
three-day, tapering course of dexamethasone (0.5, 0.3, and
0.1 mg.kg21.day21) plus separate injections of oil on P1–P3 and
then only saline and oil from P4–P6. DEXCE pups received
the same treatment as DEX pups, except that vitamins C
(200 mg.kg21.day21) and E (100 mg.kg21.day21) were adminis-
tered over the entire treatment period in addition to the three-day
tapering course of dexamethasone. CtrlCE pups received
injections of vitamin C and E from P1–6. The dose and duration
of dexamethasone used in this study was derived from and is
proportional to the 21-day tapering course of dexamethasone used
in human preterm infants to prevent or lessen CLD, starting at
0.5 mg.kg21 [36]. Ascorbic acid and a-tocopherol are often
combined to promote antioxidant activity; this combination is
essential for preventing pro-oxidant activity of the a-tocopheroxyl
radical, which is formed from a-tocopherol during lipid peroxi-
dation [32,38]. Ascorbate regenerates a-tocopherol from a-
tocopheroxyl radicals, thus preserving the antioxidant role of a-
tocopherol [38,39]. The doses of vitamins C and E used in this
study were adopted from studies indicating successful antioxidant
effects in adult Wistar rats at these levels [40]. Body weight (BW)
from P0 to P7 and every other day thereafter was recorded.
Tissue collection
During the treatment period, 10 male DEX pups, 2 male
DEXCE pups and 1 male Ctrl pup died, leaving the following
remaining male pups for study (Ctrl, n = 23; DEX, n= 14;
DEXCE, n= 26; and CtrlCE, n= 24). On P21, approximately
half of these surviving male pups from each litter (Ctrl: n = 11;
DEX: n=7; DEXCE: n= 12; CtrlCE: n= 12) were deeply
anaesthetised (0.2 mL total volume, i.p., 100 mg.mL21 ketamine,
Fort Dodge Animal Health, UK and 20 mg.mL21 xylazine,
Millpledge Veterinary, UK). To assess the symmetry of growth,
BW and crown-rump length (CRL) were determined. Brain tissue
was weighed and dissected. The hippocampal formation was
separated from the overlying cortex using a dissecting microscope
[41], then snap frozen in liquid nitrogen and stored at 280uC for
subsequent Western blot analysis. On P22, the remaining male
pups (Ctrl: n = 12; DEX: n= 7; DEXCE: n= 14; CtrlCE: n = 12)
were deeply anaesthetised as described above and perfused
intracardially with a NaCl solution (10 mM PIPES, 139 mM
NaCl, 2.7 mM KCl, 19.4 mM D-glucose, 7.5 mM PVP, pH 7.2)
followed by 4% paraformaldehyde (PFA). Brains were collected,
weighed and stored overnight at 4uC in 4% PFA for subsequent
stereological analysis. Dissection for isolation of tissue for freezing
and fixing was performed on separate days to accommodate the
number of animals to be processed within a 24-hour period.
Histology and stereology
Tissue preparation. The cerebrumwas exhaustively sectioned
at 50 mm using a Leica RM 2235 vibratome (Leica Microsystems,
Germany). Tissue was then stored in cyroprotectant at 220uC until
histological and immunohistochemical staining was performed. All
subsequent quantitative analyses were performed with the observer
blind to the treatment group.
Immunohistochemistry. Sections were washed for 30 min-
utes in phosphate buffered saline (PBS, Sigma-Aldrich, U.K.),
incubated with 30% H2O2 for 5 min to block endogenous
peroxidase activity and washed in PBS for 30 minutes. Subse-
quently non-specific binding was blocked with 4% BSA in PBS for
10 min. Sections were then incubated with primary antibody
(MBP; 1:400, Millipore, UK; NeuN, 1:400, Millipore, UK) in
primary diluent (2% BSA in PBS containing 0.3% Triton; Sigma
Aldrich, U.K.) overnight. The following day sections were washed
30 minutes in PBS, incubated for 1 hour with secondary antibody
Glucocorticoids, Oxidative Stress and the Brain
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the appropriate p l e
(1:400, Vector Laboratories, USA) in secondary diluent (2% BSA
in PBS) then washed for 15 minutes in PBS. Sections were
incubated for 1 hour in AB (Vector Laboratories, U.K.) in PBS
then washed in PBS for 15 minutes. Staining was visualized by
adding metal DAB (Thermo Scientific, UK) in peroxide buffer
(Thermo Scientific, UK) for 2 minutes to the sections. Tissue was
then mounted with 0.5% gelatine in PBS on slides.
Volumetric analysis. To assess the volume of the cerebrum
and its compartments, systematic random sampling [42] was used
to select, without bias, 10 sections per animal for analysis. Selected
sections were stained using 1% Cresyl Violet. A point grid was
superimposed on the sections and viewed using a61.25 objective.
The volume of both the left and right hemispheres, the cortex,
white matter, and the hippocampus, were analysed. Points falling
on each compartment were counted and the Cavalieri principle
(Gundersen et al, 1998) was applied in order to calculate estimated
volumes:
V objð Þ~t|Sa~t|a pð Þ|SP
Where V(obj) represents the estimated volume of the brain region, t
is the total length of the brain (t=no. of sections6section
thickness), a(p) is the area associated with each point and SP is
the sum of points for that formation. All volumetric quantifications
were performed with an Olympus BX-50 microscope and CAST
grid.
Neuronal number and soma volume quantification.
Neuronal number was estimated by using the fractionator method.
All available NeuN stained sections containing the cortex and
hippocampus (divided into the CA1, CA2/3 and dentate gyrus)
were sampled using anOlympus BX-50microscope and CAST grid
(Fig. 1). Step motors on the microscope were used to randomly
sample a known fraction of the tissue. This was achieved by
calibrating the lengths of the X and Y steps. An unbiased counting
frame of known dimensions was superimposed on the tissue image.
Nuclei within the counting frame, or those touching the permitted
lines of the counting frame, were counted. To calculate total
neuronal number, the following formula was applied:
estN~S n:f1:f2
where est N is the estimated total number of nuclei, S n is the sum of
nuclei counted in the brain sample, f1 is the reciprocal of the
sampling fraction, and f2 is the areal sampling fraction.
The soma volume of neurons from the cortex and the different
regions of the hippocampus were calculated using the vertical
dissector tool in the CAST grid programme, which generates two
orthogonal lines through the mid-point of the neuron. The
boundaries of the neuron were then identified at the intersections
of these lines with the cell membrane. Soma volume was




where In refers to the distance from the mid-point of the neuron to
the cell membrane of the neuron.
Figure 1. Photomicrograph of coronal brain section. Cresyl violet-stained sections showing the regions used for determining neuronal number
and soma volumes. These parameters were measured in the following fields: cortex (Cx), CA1, CA2/3 and dentate gyrus (DG). Scale bar = 2.5 mm.
doi:10.1371/journal.pone.0021142.g001
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Myelination. To assess the extent of myelination, the optical
density (OD) of MBP-stained fibres was measured in the corpus
callosum and cortex using ImageJ (V1.38, National Institutes of
Health). On the basis of anatomical landmarks, equivalent sections
from all rats were chosen. A calibrated optical density step tablet
was used to calibrate the images to optical density. Eight fields
within the corpus callosum and cortex were examined over three
sections per animal. Optical density was measured as grey levels.
Non-specific background ODs were measured at each brain level
in a region devoid of MBP-immunostaining and these were
subtracted from the corpus callosum and cortex values. The area
of MBP-positive fibres in the cortex, relative to cortical size, was
also assessed using the same software.
Western blotting
Western blots were performed using 20 mg aliquots of protein,
resolved on 10–12% SDS-PAGE gels. Proteins were transferred
to polyvinylidene fluoride Immobilon-P membranes (Millipore,
UK) by electroblotting. Membranes were blocked at room
temperature for 1 hour with 5% dry skim milk in tris-buffered-
saline containing 1% Tween-20 (TBS-T, Sigma-Aldrich, UK).
Purified antibodies to b-actin (1:50,000, Sigma-Aldrich, UK),
nitrotyrosine (NT; 1:2,000, Zymed Laboratories, USA), 4-
hydroxynonenal (4-HNE; 1:2,000, Calbiochem, Germany), or
heat shock protein 70 (Hsp70; 1:20,000, Stressgen, UK) in 5%
milk in TBS-T were added, and incubated at 4uC overnight.
Membranes were washed in TBS-T, incubated for 1 hour in a
secondary antibody conjugated to horseradish peroxidase (donkey
anti-rabbit IgG or sheep anti-mouse IgG; 1:10,000, GE
Healthcare, UK) and washed in TBS-T. Proteins were visualised
using enhanced chemiluminescence (ECL, Amersham, UK),
exposed to X-ray film and films were developed (Fuji FPM100A
Processor). Bands densities were quantified and expressed relative
to b-actin (ImageJ software, NIH).
Statistical Analysis
Data are presented as mean 6 SEM unless otherwise
indicated. Data were analysed by One-Way ANOVA followed
by the Student-Newman-Keuls or Tukey post hoc test. SigmaStat
software (SigmaStat for Windows, Version 2.0) was used for all
statistical analyses. P values,0.05 were accepted as statistically
significant.
Results
Body and brain weights
Compared to control offspring, DEX, with or without vitamins,
reduced body weight at weaning (Fig. 2A; P,0.05) Absolute brain
weight was not altered between the groups (Fig. 2B; P.0.05),
however, the brain to body weight ratio was significantly increased
in DEX offspring, but not DEXCE offspring when compared to
Ctrl offspring (Fig. 2C; P,0.05).
Histological Analysis
Gross morphology. Examination of the cresyl violet-stained
coronal sections did not reveal any gross alterations in cytoarchi-
tecture, cellular morphology, or anatomical organisation of the
cortex or hippocampus between the groups at P22.
Regional brain volumes. cytoarchitectureThe volume of
the cerebrum was significantly decreased in DEX offspring (Fig. 3;
P,0.05). Dexamethasone in combination with vitamins did not
significantly alter total brain volume (P,0.05). No further
alterations in absolute regional volumes were observed between
the groups (data not shown; P.0.05). Absolute regional volumes
and regional volumes relative to total brain volume, were also
unaltered (data not shown; P.0.05).
Neuronal numbers and soma volumes. There were no
differences between the groups in neuronal numbers in either the
cortex or hippocampus (Table 1, P.0.05). However, in DEX-
treated offspring compared to control offspring, soma volume was
significantly reduced in both the CA1 region and the dentate gyrus
of the hippocampus (Fig. 4 A, C; P,0.05). Soma volume was not
different between the groups in the CA2/3 region of the
hippocampus (Fig. 4B; P.0.05). Soma volumes in the CA1 and
dentate gyrus were unaltered in DEXCE offspring (P,0.05).
Myelination. cytoarchitectureThe OD of MBP-stained fibres
was significantly increased in the corpus callosum of DEXCE
offspring when compared to Ctrl offspring (Ctrl: 0.21160.006;
DEX: 0.25160.029 DEXCE: 0.29960.021; CtrlCE: 0.2596
0.016, Fig. 5; P,0.05). There were no significant differences
between the groups in relation to the OD of MBP-stained fibres in
the cortex (Ctrl: 0.18460.008; DEX: 0.17660.024; DEXCE:
0.20460.014; CtrlCE: 0.18560.01; P.0.05), or the extent of
myelination (Ctrl: 58.960.8%; DEX: 58.960.8%; DEXCE:
56.561.0%; CtrlCE: 61.962.3%; P.0.05).
Figure 2. Body, brain and brain: body weight. (A) Body weight, (B) brain weight and (C) brain: body weight at postnatal day 22 in control (Ctrl,
n = 5), dexamethasone (DEX, n = 5), dexamethasone with vitamins C and E (DEXCE, n = 5), and control with vitamins C and E (CtrlCE, n = 5) pups. *,
P,0.05 versus Ctrl; #, P,0.05 versus CtrlCE (One-Way ANOVA+Student-Newman-Keuls).
doi:10.1371/journal.pone.0021142.g002
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Western blot analysis
At P21, DEX increased the protein expression in the cortex of three
established molecular indices of oxidative stress: Hsp70 (+68%), 4-
HNE (+118), andNT (+20%, Fig. 6A–C; P,0.05). Dexamethasone in
combination with vitamins did not significantly alter Hsp70 protein
expression relative to control or DEX-treated offspring (+9%;
P,0.05). However, 4-HNE (+95%) and NT (+24%) remained up-
regulated in the cortex (P,0.05). Relative to control offspring, no
significant alterations in protein expression were observed in the
hippocampus of DEX (Hsp70: +4%; 4-HNE:26%; NT:25%, data
not shown; P.0.05) or DEXCE offspring (Hsp70: 221%; 4-HNE:
21% ; NT:228%, data not shown; P.0.05). Treatment of neonates
with vitamins alone increased Hsp70 (+63%) and 4-HNE (+73%) in
the cortex (Fig. 6 A, B; P,0.05,), and NT in both the cortex (+22%,
Fig. 6C; P,0.05) and hippocampus (+35%, data not shown; P,0.05).
Discussion
The data show that postnatal treatment with dexamethasone in
human clinically-relevant doses decreased total brain volume and
reduced neuronal soma volume in the CA1 and dentate gyrus of
the hippocampus. The study adds the novel observation that co-
administration of antioxidant vitamins with dexamethasone
improved total brain volume and neuronal soma volumes in the
hippocampus. Postnatal treatment with dexamethasone also
increased three molecular indices of oxidative stress in the cortex.
Co-administration of antioxidant vitamins restored Hsp70 protein
expression in the cortex, however the expression of 4-HNE and
NT remained significantly elevated. Treatment of neonates with
vitamins alone induced oxidative stress in the cortex.
In the present study, morphological analysis of brain tissue
revealed that volume of the cerebrum was significantly decreased
in dexamethasone-treated offspring when compared to controls.
Importantly, co-administration of dexamethasone with antioxi-
dant vitamins prevented this effect. As there were no regional
alterations in brain volumes when expressed relative to total brain
volume, it appears that the brains of the dexamethasone-treated
offspring were proportionally smaller. A decrease in whole
cerebral tissue volume may be explained by reductions in neuronal
numbers, soma volumes and/or delayed dendritic growth. To
explore these possibilities, total neuronal numbers and soma
volumes were assessed in the cortex and hippocampus, respec-
tively. Total neuronal number was not altered following
dexamethasone treatment in either the cortex or hippocampus.
However, in dexamethasone-treated offspring, soma volume was
reduced in the CA1 and the dentate gyrus of the hippocampus.
Smaller neuronal volumes may be related to a decline in cellular
function [43], selective loss of larger neurons, which has been
observed in neurodegenerative diseases [44], or reflect neuronal
shrinkage, which often precedes neurodegeneration [45]. Dexa-
methasone may delay neuronal differentiation or dendritic growth
[13], which, in addition to the reduction in soma volumes, may
also account for the reduction in brain volume. Antioxidant
vitamin supplementation in dexamethasone-treated offspring
prevented the decrease in hippocampal soma volumes. The data
provide evidence for the powerful neuroprotective effects of
vitamins C and E following glucocorticoid therapy.
To explore the mechanisms via which clinically-relevant doses
of dexamethasone affected cerebral volume and the beneficial
effects of vitamins C and E, the present study focussed on three
established molecular indices of oxidative stress known to be
affected by glucocorticoid treatment. In humans, corticosteroid
therapy has been reported to markedly increase levels of 4-HNE
[46] and NT immunoreactivity [23]. In addition, it is established
Figure 3. Cerebrum brain volume. Brain volume of the cerebrum at
postnatal day 22 in control (Ctrl, n = 5), dexamethasone (DEX, n = 5),
dexamethasone with vitamins C and E (DEXCE, n = 5), and control with
vitamins C and E (CtrlCE, n = 5) pups. *, P,0.05 versus Ctrl (One-Way
ANOVA+Student-Newman-Keuls).
doi:10.1371/journal.pone.0021142.g003
Table 1. Neuronal numbers in the cortex and hippocampus.
Ctrl DEX DEXCE CtrlCE
Neuronal Number in Cortex (million) 20.461.1 19.060.6 18.360.6 20.9610.7
Cortical Reference Volume (mm3) 343.0614.4 293.869.6 335.8626.6 321.0616.7
Neuronal Number in CA1 (61000) 410.1624.5 413.8617.7 464.4628.4 452.6614.8
CA1 Reference Volume (mm3) 0.7960.01 0.8160.07 0.8660.07 0.9260.07
Neuronal Number in CA2/3 (61000) 440.8628.2 438.6634.2 400.8623.7 416.3633.1
CA2/3 Reference Volume (mm3) 0.7360.10 0.8160.02 0.7560.05 0.8160.10
Neuronal Number in Dentate Gyrus (61000) 870.0669.1 932.5647.7 887.2654.1 868.9694.7
Dentate Gyrus Reference Volume (mm3) 0.6460.04 0.6960.04 0.7660.04 0.7860.08
Neuronal numbers and reference volumes in the control (Ctrl, n = 5), dexamethasone (DEX, n = 5), dexamethasone with vitamins C and E (DEXCE, n = 5) and control with
vitamins C and E (CtrlCE, n = 5) pups. The reference volumes are the volumes of the cortex and compartments of the hippocampal formation (CA1, CA2/3 and dentate
gyrus) that neuronal number and soma volumes were measured in.
doi:10.1371/journal.pone.0021142.t001
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Figure 4. Soma volumes in the CA1 (A), CA2/3 (B), and dentate gyrus (C) of the hippocampus. Soma volumes in the hippocampus are
shown from the control (Ctrl, n = 5), dexamethasone (DEX, n = 5), dexamethasone with vitamins C and E (DEXCE, n = 5), and control with vitamins C
and E (CtrlCE, n = 5) groups. *, P,0.05 versus Ctrl; #, P,0.05 versus DEX (One-Way ANOVA+Student-Newman-Keuls).
doi:10.1371/journal.pone.0021142.g004
Figure 5. Photomicrograph of myelin staining. Coronal section of control (Ctrl), dexamethasone (DEX), dexamethasone with vitamins C and E
(DEXCE), and control with vitamins C and E (CtrlCE)-treated offspring stained with myelin basic protein (MBP). Overall, the optical density (OD) of
myelin staining in the corpus callosum was significantly increased in DEXCE offspring when compared to Ctrl offspring (P,0.05; One-Way
ANOVA+Student-Newman-Keuls). Scale bar = 2.5 mm.
doi:10.1371/journal.pone.0021142.g005
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that dexamethasone decreases eNOS protein and/or mRNA
expression in several tissues in the rat [20,47,48]. Dexamethasone
decreases eNOS activity, largely by limiting substrate availability,
thereby promoting eNOS uncoupling leading to further superox-
ide generation and reduced NO bioavailability [20,22,47,49]. In
the present study, dexamethasone increased the expression of
Hsp70, 4-HNE, and NT in the cortex. Vitamin administration
attenuated the increase in Hsp70 protein expression induced by
dexamethasone treatment; however, the up-regulation of 4-HNE
and NT remained unchanged. Similarly, previous studies have
reported that vitamin C supplementation attenuated the increase
in Hsp70 expression in muscle following physiological oxidative
stress induced by exercise [50]. Vitamin C and E supplementation
in combination could also decrease Hsp70 expression in the brain
following heat stress [51]. Data in the present study therefore
confirm that clinically-relevant doses of dexamethsone induce
oxidative stress in the developing brain and that antioxidant
therapy partially protect against this effect. The lack of demon-
strable structural and neuronal injury, particularly in the cortex
where oxidative stress was evident, may not necessarily imply
normal function following postnatal glucocorticoid therapy. For
instance, oxidative or nitrosative stressed neurons, injured by free
radicals, might be present physically but be non-functional
[52,53]. Further, clinical evidence does suggest that early postnatal
dexamethasone therapy can have long-term adverse neuromotor
and cognitive outcomes [8,9].
The physiology underlying the inhibitory effects of antioxidant
vitamins on the expression of Hsp70 in past and present studies is
likely multi-factorial and these mechanisms may also relate to the
protective effect of antioxidants against glucocorticoid-induced
reduction in cerebral volume, as shown in the present study. For
instance, in addition to quenching ROS directly [39], antioxidant
vitamins can act through tetrahydrobiopterin (BH4) to stimulate
NO production by endothelial NO synthase [54]. Antioxidant
vitamins can also prevent the S-nitrosylation of sensitive thiol groups
on endothelial NO synthase, thereby maintaining their stability and
the affinity of NO synthase for BH4 [55]. Further, it has been
reported that vitamin C may enhance the expression and/or action
of potent antioxidant enzymes [56]. Since manipulation of the
vascular NO:NO2
2 ratio is an important determinant of vascular
tone, whereby a decrease in the ratio promotes vasoconstriction and
an increase leads to vasodilatation [57], glucocorticoid-induced
oxidative stress will favour a decrease in perfusion and antioxidant
therapy will oppose this. Accordingly, several studies have shown
that clinically-relevant dosing regimens of glucocorticoids in
perinatal practice increase vascular resistance in several vascular
beds, including the cerebral circulation [58–60]. Any effects of
antioxidant vitamins which enhance the bioavailability of NO will
favour maintained perfusion and thereby a protection against the
stunting effects of glucocorticoids on growth, particularly on
circulations which are highly dependent of NO, such as the cerebral
vascular bed.
The mechanisms underlying the region-specific pattern of
cerebral oxidative stress reported in the present paper are not
well understood. One explanation may be that the neuronal
populations in the cortex show greater vulnerability to oxidative
stress as a result of a greater oxidative burden and/or lower
antioxidant protection. Alternatively, it is possible that the
hippocampus may have shown early changes in markers of
oxidative stress following postnatal glucocorticoid treatment, but
that these indices were below the threshold of detection with
available techniques or that they had subsided by the time of tissue
collection.
>Additional data in the present study show that treatment
of neonates with vitamins alone increased Hsp70 and 4-HNE in
the cortex, and NT in both the cortex and hippocampus. Although
antioxidant vitamin supplementation may improve disease states
and/or conditions associated with enhanced oxidative stress,
antioxidant treatment in healthy conditions where the physiology
of the individual is already replenished with an appropriate
equilibrium of pro- and anti-oxidant mechanisms, may, in fact,
lead to excess NO bioavailability. The latter will promote
peroxynitrite generation, thereby mimicking oxidative stress
with subsequent induction of a number of the unwanted side-
effects [61,62]
Postnatal dexamethasone treatment, with or without vitamins,
significantly reduced body weight at P22. Maternal antenatal
treatment with glucocorticoids has been shown to reduce weight
gain in human infants [63] and suppress growth until weaning in
rats [64]. Postnatally, glucocorticoids reduce somatic growth in
premature human infants [65]. Our results also confirm similar
findings reported in other experimental studies [36,37,66–68].
Figure 6. Expression of heat-shock protein 70 (Hsp70, 70 KDa, A), 4-hydroxynonenal (4-HNE, 54 kDa, B), and nitrotyrosine (NT,
35 kDa, C) in the cortex. Representative Western blots are shown from the control (Ctrl, n = 6), dexamethasone (DEX, n = 6), dexamethasone with
vitamins C and E (DEX CE, n = 6), and control with vitamins C and E (CtrlCE, n = 6) groups. Expression of the proteins was quantified and expressed as a
ratio to b-actin. *, P,0.05 versus Ctrl; #, P,0.05 versus DEX; ,, P,0.05 versus CtrlCE (One-Way ANOVA+Student-Newman-Keuls).
doi:10.1371/journal.pone.0021142.g006
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This reduction in somatic weight is likely due to the well-described
direct effects of glucocorticoids on overall tissue accretion and
catabolism [69–71] rather than the effects of glucocorticoid-
induced oxidative stress on perfusion of regional circulations.
Dexamethasone appeared to have a greater effect on body weight
than brain weight (brain sparing), which suggests an increase in
vascular resistance in peripheral circulations. The peripheral
vasoconstrictor effects of dexamethasone in early life are well
known. Two separate studies have reported that treatment of fetal
sheep in late gestation with glucocorticoids leads to an increase in
vascular resistance in peripheral circulations [58,59]. In this study,
dexamethasone treatment reduced survival to 70%, a finding
supported by other studies in neonatal rat pups [72–74]. This
increase in mortality may be attributed to an inability of the
offspring to utilise nutrients, which may be due to decreased
suckling and/or accelerated gut closure [75].
In conclusion, postnatal glucocorticoid treatment in human
clinically relevant doses reduced total brain volume and soma
volumes in the hippocampus and induced oxidative stress in
the developing brain. Combined glucocorticoid and antioxidant
treatment may ameliorate some of the adverse consequences
of postnatal glucocorticoid therapy on the developing brain.
However, antioxidant vitamin supplementation is not recom-
mended in healthy offspring. The data provide the proof of
concept that antioxidant therapy may antagonise some of the
unwanted effects of potent glucocorticoids needed in clinical
practice. It is now important to investigate the value of this
combined therapy on cerebral structure and functional develop-
ment in an experimental model that closely mimics conditions
associated with premature birth in humans, including established
chronic lung disease or bronchopulmonary dysplasia.
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